Auction date2020-09-25
Coupon0.75 %
Tendered volume, SEK mln1,000 +/- 250
Volume offered, SEK mln2,850
Volume bought, SEK mln1,000
Number of bids6
Number of accepted bids4
Average yield-0.116 %
Lowest accepted yield-0.119 %
Highest yield-0.110 %
% accepted at lowest yield       5.00 %

Auction date2020-09-25
Coupon2.25 %
Tendered volume, SEK mln1,000 +/- 250
Volume offered, SEK mln2,300
Volume bought, SEK mln1,000
Number of bids6
Number of accepted bids3
Average yield0.054 %
Lowest accepted yield0.051 %
Highest yield0.056 %
% accepted at lowest yield       33.33

About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

ProMIS Neurosciences Offers its Perspective on the Likelihood of Regulatory Approval of Aducanumab21.10.2020 12:30:10 CESTPress release

Regulatory progress is spurring the development of safe and effective therapies for Alzheimer’s disease TORONTO and CAMBRIDGE, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, released a white paper today that offers its perspective on aducanumab’s likelihood of regulatory approval in advance of its U.S. Food and Drug Administration Advisory Committee (AC) review on November 6. The white paper, available at, chronicles aducanumab’s history, regulatory support, positive data outcomes and potential impetus for development of improved second-generation therapies. If approved, aducanumab would be the first disease-modifying treatment for Alzheimer’s disease, offering a therapeutic option for the millions of Americans living with the disease. A

Orion Group Interim Report 1-9/202021.10.2020 11:00:00 CESTPress release

ORION CORPORATION INTERIM REPORT 1-9/2020 21 OCTOBER 2020 at 12:00 noon EEST Orion Group Interim Report 1-9/2020 This is a summary of Orion’s Interim Report 1-9/2020. The complete report is attached to this stock exchange release and is available at Net sales were EUR 823 million (EUR 776 million in January–September 2019).Operating profit was EUR 246 (198) million.Both net sales and operating profit include a total of EUR 37 (47) million milestone payments.Profit before taxes was EUR 245 (196) million.Equity ratio was 70% (78%).ROCE before taxes was 40% (32%).ROE after taxes was 34% (28%).Basic earnings per share were EUR 1.38 (1.10).Cash flow per share before financial items was EUR 1.52 (1.28).Outlook for 2020 was updated after the review period on 19 October 2020. Orion estimates that in 2020 net sales will be at a similar level as in 2019 or slightly higher than in 2019 (net sales in 2019 were EUR 1

Prosafe SE: Q3 2020 results and audio webcast on 5 November 202021.10.2020 10:34:42 CESTPress release

Prosafe SE will release its third quarter 2020 results on 5 November 2020 at approx. 07:00 a.m. CET. The Q3 2020 report and the Q3 2020 presentation will be published on and on Prosafe’s website Jesper Kragh Andresen, CEO and Stig H. Christiansen, Deputy CEO & CFO will the same day at 10:00 a.m. CET host an audio webcast. The audio webcast can be followed at It will be possible to submit questions during the presentation by using the Q&A tool embedded in the audio webcast. These questions will be answered after the presentation. A replay of the audio webcast will be made available at shortly after. Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to Stavanger, 21 October 2020 Prosafe SE For further information, please contact: Jesper K. Andresen, CEO Phone: +47 51 65 24

Result of Riksbank´s purchases of Commercial Paper21.10.2020 10:00:00 CESTPress release

Auction date201021 Requested volume, SEK mln4,000 Credit rating class1Term3MFixed purchase rate0.45 %Total bid amount, SEK mln0,000Prel. accepted volume, SEK mln0,000Percentage alloted0.00 %Number of bids0 Credit rating class1Term6MFixed purchase rate0.55 %Total bid amount, SEK mln0,000Prel. accepted volume, SEK mln0,000Percentage alloted0.00 %Number of bids0 Credit rating class2Term3MFixed purchase rate0.75 %Total bid amount, SEK mln0,000Prel. accepted volume, SEK mln0,000Percentage alloted0.00 %Number of bids0 Credit rating class2Term6MFixed purchase rate0.85 %Total bid amount, SEK mln0,000Prel. accepted volume, SEK mln0,000Percentage alloted0.00 %Number of bids0

Recovery mitigates pandemic’s impact on central government finances21.10.2020 09:30:00 CESTPress release

Recovery mitigates pandemic’s impact on central government finances The Swedish economy is recovering after the historically large fall in GDP in the second quarter of 2020. This helps to support central government finances, reduce the borrowing requirement compared with the previous forecast and dampen the debt increase resulting from the pandemic. The Swedish National Debt Office’s new forecast shows a central government budget deficit of SEK 256 billion this year, an improvement in the budget balance by SEK 146 billion over the previous forecast from May. The reduced deficit means the Debt Office is lowering borrowing and that central government debt is not expected to increase as much as previously forecast. “The virus outbreak has had a major impact on the Swedish economy and state finances, but the development in recent months indicates it is less than we forecast in May. Not least the trend in tax income points to the start of an increasingly more apparent economic recovery, alt

Återhämtning mildrar pandemins effekter på statsfinanserna21.10.2020 09:30:00 CESTPressemelding

Återhämtning mildrar pandemins effekter på statsfinanserna Svensk ekonomi återhämtar sig efter det historiskt stora BNP-tappet under det andra kvartalet 2020. Det bidrar till att understödja statsfinanserna, minska statens lånebehov jämfört med tidigare prognos och dämpa ökningen av statsskulden till följd av pandemin. Riksgäldens nya prognos visar ett underskott i statsbudgeten på 256 miljarder kronor i år, en förbättring av budgetsaldot med 146 miljarder kronor jämfört med föregående prognos från maj. Det minskade underskottet innebär att Riksgälden drar ned statens upplåning och att statsskulden inte väntas öka lika mycket som tidigare förutspåtts. – Virusutbrottet har haft stora effekter på svensk ekonomi och statens finanser, men de senaste månadernas utveckling indikerar att de blir mindre än vi bedömde i maj. Inte minst utvecklingen av skatteinkomsterna pekar på att ekonomin har börjat återhämta sig allt tydligare, men osäkerheten är fortfarande stor, säger riksgäldsdirektör Han